Press briefing 1 Lung and Gynaecological cancers
Moderator and Commentator LBA5_PR: Pilar Garrido, Spain
Commentator LBA4_PR: Marina Garassino, Italy
Commentator LBA2_PR: Susana Banerjee, UK
Link to press releases and abstracts
- LBA2_PR - Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Isabelle Ray-Coquard, France - LBA5_PR - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
Suresh Ramalingam, US - LBA4_PR - Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis
Solange Peters, Switzerland - Discussion Q & A ESMO 2019 Press conference Oavrial & Lung cancer
More Press releases with links to abstracts:
LBA68_PR | 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma |
LBA30_PR | Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration |
LBA81_PR[nbsp | Phase II/III blood-first assay screening trial (BFAST) in treatment-naïve NSCLC: initial results from the ALK+ cohort |